CD8A and neoplasm: We further proved that combination therapy dramatically increased the tumor-infiltrating lymphocytes and tumor-antigen-specific T cells as well as the CD8/Treg ratio in the tumor microenvironment, as compared to β-lap or anti-PD-L1 monotherapy.